Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

关键词: acylcarnitine;    biomarkers;    diabetic nephropathies;    metabolomics;    mitochondrial dysfunction;   

DOI  :  

来源: DOAJ

【 摘 要 】

Xiaodie Mu,1,* Min Yang,1,* Peiyao Ling,1,* Aihua Wu,1 Hua Zhou,1 Jingting Jiang2 1Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People’s Republic of China; 2Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua Zhou; Jingting JiangDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, People’s Republic of China, Tel [phone], Email [e-mail]; [e-mail]: Diabetic nephropathy (DN), one of the most serious microvascular complications of diabetes mellitus (DM), may progress to end-stage renal disease (ESRD). Current biochemical biomarkers, such as urinary albumin excretion rate (UAER), have limitations for early screening and monitoring of DN. Recent studies have identified some metabolites as candidate biomarkers for early detection of DN. In this review, we summarize the role of dysregulated acylcarnitines (AcylCNs) in DN pathophysiology. Lower abundance of short- and medium-chain AcylCNs and higher long-chain AcylCNs often occurred in DM with normal albuminuria and microalbuminuria, compared with advanced stages of DN. The increase of long-chain AcylCNs was supposed to be an adaptive compensation in fat acids (FAs) oxidation in the early stage of DN. Conversely, the decrease of long-chain AcylCNs was due to incomplete oxidation of FAs in advanced stage of DN. Thus, AcylCNs may serve as sensitive biomarkers in predicting the risk of DN.Keywords: acylcarnitine, biomarkers, diabetic nephropathies, metabolomics, mitochondrial dysfunction

【 授权许可】

Unknown